Falk Gastro Review Journal

Current science, compiled for you from the multitude of scientific publications – this is the Falk Gastro Review Journal.

Dunkel- bis hellblaue Grafik einer Tonspur-Frequenz auf orangem Hintergund.

The latest issues

Edition 4/2024

Edition 3/2024

Edition 2/2024

Find here all FGR publications since mid-2022 selected and reviewed from international medical journals. Click here above to browse the individual quarterly issues or use the filters below or click chronologically through all articles.

All articles

Panitumumab versus bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: A randomized clinical trial

JAMA. 2023;329(15):1271−82

Prevalence of colorectal neoplasia 10 or more years after a negative screening colonoscopy in 120,000 repeated screening colonoscopies

JAMA Intern Med. 2023;183(3):183−90

Association of life expectancy with surveillance colonoscopy findings and follow-up recommendations in older adults

JAMA Intern Med. 2023;183(5):426−34

Adverse events of endoscopic full-thickness resection: Results from the German and Dutch nationwide colorectal FTRD registry

Gastrointest Endosc. 2023;97(4):780−9.e4

Effect of pre-resection biopsy on detection of advanced dysplasia in large non-pedunculated colorectal polyps un-dergoing endoscopic mucosal resection

Endoscopy. 2023;55(3):267−73

Short-term and long-term outcomes of a disruption and disconnection of the pancreatic duct in necrotizing pan-creatitis: A multicenter cohort study in 896 patients

Am J Gastroenterol. 2023;118(5):880−91

Association of statin usage and the development of diabetes mellitus after acute pancreatitis

Clin Gastroenterol Hepatol. 2023;21(5):1214−22.e14

EUS-guided drainage of large walled-off pancreatic necroses using plastic versus lumen-apposing metal stents: A single-center randomized controlled trial

Gut. 2023;72(6):1167–73

Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: Results from a randomized, open-label, phase 3 trial

J Clin Oncol. 2023;41(11):2007–19